The field of gastroenterology has been revolutionized by the availability of targeted biologic treatments. Current gastroenterology dynamics the REACH team is tracking include:
- First approvals in difficult-to-treat GI conditions (e.g., Dupixent as the first FDA-approved treatment for Eosinophilic Esophagitis)
- Increased understanding of role of gut microbiota in gastroenterological conditions
- Increasing incidence of GI conditions such as Irritable Bowel Syndrome (IBS), Gastroesophageal Reflux Disease (GERD) and Celiac Disease
Search Gastroenterology diseases we cover
